[go: up one dir, main page]

SMT202000659T1 - Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 - Google Patents

Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2

Info

Publication number
SMT202000659T1
SMT202000659T1 SM20200659T SMT202000659T SMT202000659T1 SM T202000659 T1 SMT202000659 T1 SM T202000659T1 SM 20200659 T SM20200659 T SM 20200659T SM T202000659 T SMT202000659 T SM T202000659T SM T202000659 T1 SMT202000659 T1 SM T202000659T1
Authority
SM
San Marino
Prior art keywords
masp
methods
conditions associated
complement activation
treating conditions
Prior art date
Application number
SM20200659T
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Gregory A Demopulos
Thomas Dudler
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of SMT202000659T1 publication Critical patent/SMT202000659T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
SM20200659T 2013-10-17 2014-10-17 Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 SMT202000659T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361892283P 2013-10-17 2013-10-17
US201462020845P 2014-07-03 2014-07-03
PCT/US2014/061236 WO2015058143A1 (en) 2013-10-17 2014-10-17 Methods for treating conditions associated with masp-2 dependent complement activation
EP14853910.9A EP3057993B1 (en) 2013-10-17 2014-10-17 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (1)

Publication Number Publication Date
SMT202000659T1 true SMT202000659T1 (it) 2021-01-05

Family

ID=52828769

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200659T SMT202000659T1 (it) 2013-10-17 2014-10-17 Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2

Country Status (25)

Country Link
US (3) US20150166675A1 (it)
EP (2) EP3057993B1 (it)
JP (3) JP2016539919A (it)
KR (3) KR102744762B1 (it)
CN (2) CN111588855A (it)
AU (2) AU2014337047B2 (it)
BR (1) BR112016008409B1 (it)
CA (1) CA2926385A1 (it)
CL (2) CL2016000908A1 (it)
CY (1) CY1123776T1 (it)
DK (1) DK3057993T3 (it)
ES (1) ES2829913T3 (it)
HR (1) HRP20201733T1 (it)
HU (1) HUE051746T2 (it)
IL (2) IL283373B2 (it)
LT (1) LT3057993T (it)
MX (2) MX389699B (it)
NZ (2) NZ719476A (it)
PL (1) PL3057993T3 (it)
PT (1) PT3057993T (it)
RS (1) RS61351B1 (it)
RU (1) RU2718850C2 (it)
SI (1) SI3057993T1 (it)
SM (1) SMT202000659T1 (it)
WO (1) WO2015058143A1 (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ731596A (en) 2011-04-08 2022-07-01 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PT3057993T (pt) 2013-10-17 2020-11-19 Omeros Corp Métodos de tratamento das condições associadas à ativação do complemento dependente do masp-2
MX2018005165A (es) 2015-11-09 2020-11-11 Omeros Corp Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
WO2017120344A1 (en) * 2016-01-05 2017-07-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP6865767B2 (ja) * 2016-03-31 2021-04-28 オメロス コーポレーション 血管形成の阻害を必要とする対象において血管形成を阻害するための方法
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI881481B (zh) * 2017-08-15 2025-04-21 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
CA3072913A1 (en) * 2017-08-25 2019-02-28 Omeros Corporation Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome
CN108171772B (zh) * 2017-12-28 2021-11-19 中国地质调查局西安地质调查中心 利用mapGIS、CJKCOOR_Ver和DELF3D提取河流边界的方法
JP7536655B2 (ja) 2018-05-29 2024-08-20 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
MA53234A (fr) * 2018-06-22 2022-04-20 Omeros Corp Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques
DK3893924T3 (da) * 2018-12-13 2024-11-04 argenx BV Antistoffer til human komplementfaktor C2B og anvendelsesfremgangsmåder
CN111134250A (zh) * 2019-12-03 2020-05-12 海南大学 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
EP4069358A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110531A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN115300608B (zh) * 2021-05-06 2023-06-02 四川大学 一种利用甘露糖结合凝集素阻断新冠病毒感染的方法
EP4444758A2 (en) * 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
WO2025076476A2 (en) 2023-10-06 2025-04-10 Omeros Corporation Masp-2 inhibitors and methods of use
CN119143861B (zh) * 2024-11-19 2025-01-24 四川大学 一种甘露聚糖结合凝集素改造蛋白ppg-rep-MBL、DNA分子、表达载体、宿主细胞，以及用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
ATE399025T1 (de) 1999-07-21 2008-07-15 Omeros Corp Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
PT1625166E (pt) * 2003-05-12 2015-08-20 Helion Biotech Aps Anticorpos para masp-2
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20130266559A1 (en) * 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2386315A1 (en) 2004-06-10 2011-11-16 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
HUE061548T2 (hu) * 2008-11-10 2023-07-28 Alexion Pharma Inc Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
WO2011006982A2 (en) 2009-07-17 2011-01-20 Rigshospitalet Inhibitors of complement activation
PT2488203T (pt) 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
AU2011223866B2 (en) 2010-03-01 2015-05-21 Alexion Pharmaceuticals Inc. Methods and compositions for treating Degos' disease
NZ731596A (en) * 2011-04-08 2022-07-01 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
CN107011443B (zh) * 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
JP2013030593A (ja) 2011-07-28 2013-02-07 J Devices:Kk 半導体装置、該半導体装置を垂直に積層した半導体モジュール構造及びその製造方法
KR20220100997A (ko) 2012-06-18 2022-07-18 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
US10815296B2 (en) 2013-09-16 2020-10-27 Children's Hospital Medical Center Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
PT3057993T (pt) 2013-10-17 2020-11-19 Omeros Corp Métodos de tratamento das condições associadas à ativação do complemento dependente do masp-2
MX2018005165A (es) 2015-11-09 2020-11-11 Omeros Corp Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.

Also Published As

Publication number Publication date
RS61351B1 (sr) 2021-02-26
RU2020111211A (ru) 2021-11-08
CN105683219B (zh) 2020-07-14
SI3057993T1 (sl) 2021-03-31
US20240124611A1 (en) 2024-04-18
LT3057993T (lt) 2020-11-25
CL2018001557A1 (es) 2018-07-20
KR20160062186A (ko) 2016-06-01
JP2020037568A (ja) 2020-03-12
EP3750919A1 (en) 2020-12-16
AU2014337047B2 (en) 2020-03-12
US20200157244A1 (en) 2020-05-21
MX2016005017A (es) 2016-11-07
IL245115B (en) 2022-05-01
PL3057993T3 (pl) 2021-02-08
ES2829913T3 (es) 2021-06-02
RU2718850C2 (ru) 2020-04-15
NZ719476A (en) 2022-07-29
EP3057993A4 (en) 2017-09-13
HRP20201733T1 (hr) 2021-02-05
MX2021008044A (es) 2021-10-13
US11525011B2 (en) 2022-12-13
KR102744762B1 (ko) 2024-12-20
IL283373B2 (en) 2024-08-01
EP3057993B1 (en) 2020-08-12
IL245115A0 (en) 2016-06-30
KR20240101700A (ko) 2024-07-02
BR112016008409A2 (pt) 2017-10-03
CL2016000908A1 (es) 2016-12-02
EP3057993A1 (en) 2016-08-24
JP2022000467A (ja) 2022-01-04
CN111588855A (zh) 2020-08-28
IL283373A (en) 2021-07-29
NZ757986A (en) 2022-07-29
RU2016118769A (ru) 2017-11-22
CA2926385A1 (en) 2015-04-23
BR112016008409B1 (pt) 2021-06-15
AU2020203748B2 (en) 2022-08-04
CN105683219A (zh) 2016-06-15
MX389699B (es) 2025-03-20
KR102677379B1 (ko) 2024-06-24
AU2020203748A1 (en) 2020-06-25
JP6953498B2 (ja) 2021-10-27
JP7397037B2 (ja) 2023-12-12
CY1123776T1 (el) 2022-03-24
AU2014337047A1 (en) 2016-05-19
WO2015058143A1 (en) 2015-04-23
IL283373B1 (en) 2024-04-01
PT3057993T (pt) 2020-11-19
DK3057993T3 (en) 2020-11-16
RU2016118769A3 (it) 2018-11-21
JP2016539919A (ja) 2016-12-22
HUE051746T2 (hu) 2021-03-29
KR20220053057A (ko) 2022-04-28
US20150166675A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
PL3057993T3 (pl) Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od MASP-2
IL278018A (en) Methods for the treatment or prevention of ophthalmological conditions
GB2528196B (en) Multiple-qubit wave-activated controlled gate
SG10202011469UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
GB201321440D0 (en) Process
GB201312991D0 (en) Process
GB201307334D0 (en) Process
GB201316269D0 (en) Process
GB201304872D0 (en) Treatment
GB201318888D0 (en) Process
GB201321627D0 (en) Process
GB201321611D0 (en) Process
GB201313915D0 (en) Process
GB201322273D0 (en) Process
GB201320869D0 (en) Process
GB201314334D0 (en) Process
GB201307327D0 (en) Process
GB201300537D0 (en) Crosslinking process
GB201302441D0 (en) Process
GB201316253D0 (en) Process
GB201307951D0 (en) Process
GB201300073D0 (en) Process
PL2836176T3 (pl) Sposób leczenia starczowzroczności
GB201314561D0 (en) Process
GB201307310D0 (en) Treatment